Prilenia
Drug Discovery · Neurology & CNS Therapeutics
1open role
1backers · Amplitude Ventures
10+team · employees, estimated range
2018founded
Overview
Prilenia is dedicated to developing treatments for Huntington’s disease, ALS, neurodegenerative diseases & neurodevelopmental disorders.
Funding and backers
Team
11-50
employees, estimated range
Backers
1
Amplitude Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 19, 2024
New executive Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer · Nasdaq
2018
Founded
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Jobs
≈ $162k – $292k per year (Estimated) · Remote (United States) · Full-Time · 12+ years exp · Boston
Oracle
Cybersecurity
GDPR
HIPAA
Life Sciences
Good Clinical Practice
CDISC
Veeva
Medidata Rave
MedTech
21 CFR Part 11
CAPA
Apply
Growth
Hiring Momentum
36/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
Median time-to-fill
120 days
faster than 9% of the market
ATS activity
Every ~5 hours
11/04/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Leadership
50% ▲
Operations
50% ▼
Activity Timeline
Added CAPA to stack
Oct 2026
Added Veeva to stack
Oct 2026
Added Medidata Rave to stack
Oct 2026
Added Good Clinical Practice to stack
Oct 2026
Added CDISC to stack
Oct 2026
Added 21 CFR Part 11 to stack
Oct 2026
New location: United States
Oct 2026
Added Oracle to stack
Oct 2026
Added HIPAA to stack
Oct 2026
Added GDPR to stack
Oct 2026
Added Mandiant capa to stack
Oct 2026
Added Microsoft Office to stack
Sep 2026
Tech stack
Technologies named in job postings at Prilenia over the last 12 months, by layer, with the share of postings for each.
Technologies in use
8
Postings analysed
2
Stack modernity
58/100
Databases
Oracle
Cloud & platforms
GCP
Developer tools
Medidata Rave
Veeva
Practices & domains
21 CFR Part 11
CAPA
CDISC
Good Clinical Practice
Sign in to see how your skills match this stack
Sign In
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Amplitude VenturesVia a fund
27 portfolio companies: Creative Destruction Lab, Thryv Therapeutics Inc., Xap Therapeutics and 24 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Prilenia eyes 2025 launch for Huntington's drug pridopidine
Prilenia Therapeutics is planning to file its Huntington's disease drug pridopidine in the EU shortly, after mixed results in a phase 3 trial.
Read more
Report
Prilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease Research
Read more
Report
Prilenia and Ferrer Announce First Participant Enrolled in the "PREVAiLS" Phase 3 Study of Pridopidine in ALS
Read more
Report
Prilenia Therapeutics B.V.
The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Prilenia Therapeutics B.V. reflects the research output of authors from Prilenia Therapeutics B.V. who published articles in the 145 j
Read more
Report
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
NAARDEN, The Netherlands& WALTHAM, Mass.---- Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disord
Read more
Report
Prilenia Achieves 25% Enrollment in its Phase 3 HD Trial and Appoints Dr. Goldberg as CSO
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, i...
Read more
Report
Prilenia Therapeutics: Prilenia Achieves 25% Enrollment in its Phase 3 HD Trial and Appoints Dr. Goldberg as CSO
Prilenia's global phase 3 trial in Huntington's Disease (PROOF-HD) has enrolled 120 patients on schedule reaching 25% of its target PROOF-HD is the most advanced clinical trial in HD assessing
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Boston
Boston
United States
HQ
1 open roles 1 posted in 90 days 100% remote 10-50 est. staff
hires for Leadership